Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tylenol Arthritis Extended Relief

This article was originally published in The Tan Sheet

Executive Summary

New name for Tylenol Extended Relief (acetaminophen 650 mg) reflects the fact that about 60% of doctor recommendations for the product have been for the management of arthritis pain, McNeil Consumer Products says Aug. 24. In addition, over 50% of consumers taking Tylenol Extended Relief use it to treat arthritis pain, according to the firm. The new name "will make it easier to find the product on store shelves," McNeil adds. The renamed bi-layer caplets will appear in stores beginning in early September ("The Tan Sheet" July 6, In Brief)...

You may also be interested in...



Tylenol Arthritis Extended Relief Name Contested By Aspirin Foundation

The Aspirin Foundation of America is challenging the name of McNeil Consumer Healthcare's Tylenol Arthritis Extended Relief as an unapproved, false and misleading efficacy claim that renders the product misbranded.

Tylenol Arthritis Extended Relief Name Contested By Aspirin Foundation

The Aspirin Foundation of America is challenging the name of McNeil Consumer Healthcare's Tylenol Arthritis Extended Relief as an unapproved, false and misleading efficacy claim that renders the product misbranded.

Tylenol Arthritis Extended Relief Name Contested By Aspirin Foundation

The Aspirin Foundation of America is challenging the name of McNeil Consumer Healthcare's Tylenol Arthritis Extended Relief as an unapproved, false and misleading efficacy claim that renders the product misbranded.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel